Skip to main content
Graduate School of Biomedical Sciences

Recent Publications from the Huggins Lab

Wallingford MC, Tarui T, Jayaraman N, Huggins GS, Dighe MK. 2019. Application of dynamic contrast enhanced magnetic resonance imaging to evaluate angiogenic response and vascular permeability. Arterioscler Thromb Vasc Biol. 39: 1507-1509. Abstract

McCallum W, Tighiouart H, Kiernan MS, Huggins GS, Sarnak MJ. 2019. Relation of kidney function decline and NT-proBNP with risk of mortality and readmission in acute decompensated heart failure. Am J Med. Epub ahead of print. Abstract

Richards DA, Aronovitz MJ, Calamaras TD, Tam K, Martin GL, Liu P, Bowditch HK, Zhang P, Huggins GS, Blanton RM. 2019. Distinct phenotypes induced by three degrees of transverse aortic constriction in mice. Sci Rep. 9: 5844. Abstract

Baugh LM, Watson MC, Kemmerling EC, Hinds P, Huggins GS, Black LD 3rd. 2019. Knockdown of CD44 expression decreases valve interstitial cell calcification in vitro. Am J Physiol Heart Circ Physiol. 317: H26-H36 Abstract

Ngwenyama N, Salvador AM, Velázquez F, Nevers T, Levy A, Aronovitz MJ, Luster AD, Huggins GS, Alcaide P. 2019. CXCR3 regulates CD4+ T cell cardiotropism in pressure overload induced cardiac dysfunction. JCI Insight 4(7). pii: 125527. Abstract

McCaffery JM, Ordovas JM, Huggins GS, Lai CQ, Espeland MA, Tate DF, Wing RR. 2018. Weight gain prevention buffers the impact of CETP rs3764261 on high density lipoprotein cholesterol in young adulthood: The Study of Novel Approaches to Weight Gain Prevention (SNAP). Nutr Metab Cardiovasc Dis. 28: 816-821.  Abstract

Mirhashemi ME, Noubary F, Chapman-Bonofiglio S, Tzipori S, Huggins GS, Widmer G. 2018. Transcriptome analysis of pig intestinal cell monolayers infected with Cryptosporidium parvum asexual stages. Parasit Vectors 11:176. Abstract

Baugh LM, Liu Z, Quinn KP, Osseiran S, Evans CL, Huggins GS, Hinds PW, Black LD, Georgakoudi I. 2018. Non-destructive two-photon excited fluorescence imaging identifies early nodules in calcific aortic-valve disease. Nat Biomed Eng. 1: 914-924. Abstract

Freytsis M, Baugh L, Liu Z, Georgakoudi I, Hinds PW, Black LD, Huggins GS. 2018. Conditional deletion of RB1 in the Tie2 lineage leads to aortic valve regurgitation. PLoS One 13: e190623. Abstract

Berger SE, Huggins GS, McCaffery JM, Lichtenstein AH. 2017. Comparison among criteria to define successful weight-loss maintainers and regainers in the Action for Health in Diabetes (Look AHEAD) and Diabetes Prevention Program trials. Am J Clin Nutr. 106: 1337-1346. Abstract

Freeman LM, Rush JE, Stern JA, Huggins GS, Maron MS. 2017. Feline hypertrophic cardiomyopathy: A spontaneous large animal model of human HCM. Cardiol Res. 8: 139-142. Abstract

Lynch TL 4th, Kuster DWD, Gonzalez B, Balasubramanian N, Nair N, Day S, Calvino JE, Tan Y, Liebetrau C, Troidl C, Hamm CW, Güçlü A, McDonough B, Marian AJ, van der Velden J, Seidman CE, Huggins GS, Sadayappan S. 2017. Cardiac myosin binding protein-C autoantibodies are potential early indicators of cardiac dysfunction and patient outcome in acute coronary syndrome. JACC Basic Transl Sci. 2: 122-131. Abstract

de Denus S, Rouleau JL, Mann DL, Huggins GS, Pereira NL, Shah SH, Cappola TP, Fouodjio R, Mongrain I, Dubé MP. 2017. CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction. Pharmacogenomics Epub ahead of print. Abstract

Ferrés MA, Bianchi DW, Siegel AE, Bronson RT, Huggins GS, Guedj F. 2016. Perinatal natural history of the Ts1Cje mouse model of Down syndrome: Growth restriction, early aortality, heart defects, and delayed development. PLoS One 11: e0168009. Abstract

Morine KJ, Paruchuri V, Qiao X, Aronovitz M, Huggins GS, DeNofrio D, Kiernan MS, Karas RH, Kapur NK. 2016. Endoglin selectively modulates transient receptor potential channel expression in left and right heart failure. Cardiovas Pathol. 25: 478-482.  Abstract

de Denus S, Rouleau JL, Mann DL, Huggins GS, Cappola TP, Shah SH, Keleti J, Zada YF, Provost S, Bardhadi A, Phillips MS, Normand V, Mongrain I, Dubé MP. 2016. A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials. Pharmacogenomics 17: 192-200. Abstract

Huggins GS. 2016. Genetic susceptibility to oxidative stress and cardiovascular disease. EBioMedicine 2: 1864-1865. Abstract

Ellis KL, Zhou Y, Rodriguez-Murillo L, Beshansky JR, Ainehsazan E, Selker HP, Huggins GS, Cupples LA, Peter I. 2015. Common variants associated with changes in levels of circulating free fatty acids after administration of glucose-insulin-potassium (GIK) therapy in the IMMEDIATE trial. Pharmacogenomics Epub ahead of print.  Abstract

Alkofide H, Huggins GS, Beshansky JR, Ruthazer R, Peter I, Ray M, Mukherjee JT, Selker HP. 2015. C-Reactive protein reactions to glucose-insulin-potassium infusion and relations to infarct size in patients with acute coronary syndromes. BMC Cardiovasc Disord. 15: 163.  Abstract

Belalcazar LM, Papandonatos GD, Erar B, Peter I, Alkofide H, Balasubramanyam A, Brautbar A, Kahn SE, Knowler WC, Ballantyne CM, McCaffery JM, Huggins GS; Genetics Subgroup of the Look AHEAD Study. 2015. Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein (GCKR) Inhibition: GCKR-Leu446Pro Variant in Look AHEAD. Circ Cardiovasc Genet. Epub ahead of print.  Abstract

Alkofide H, Huggins GS, Ruthazer R, Beshansky JR, Selker HP. 2015. Serum adiponectin levels in patients with acute coronary syndromes: Serial changes and relation to infarct size. Diab Vasc Dis Res. 12: 411-419.  Abstract

Ellis KL, Zhou Y, Beshansky JR, Ainehsazan E, Selker HP, Cupples LA, Huggins GS, Peter I. 2015. Genetic modifiers of response to glucose-insulin-potassium (GIK) infusion in acute coronary syndromes and associations with clinical outcomes in the IMMEDIATE trial. Pharmacogenomics 15: 488-495. Abstract

Belalcazar LM, Papandonatos GD, McCaffery JM, Peter I, Pajewski NM, Erar B, Allred ND, Balasubramanyam A, Bowden DW, Brautbar A, Pi-Sunyer FX, Ballantyne CM, Huggins GS. 2015. A common variant in the CLDN7/ELP5 locus predicts adiponectin change with lifestyle intervention and improved fitness in obese individuals with diabetes. Physiol Genomics 47: 215-224. Abstract

Yutzey KE, Demer LL, Body SC, Huggins GS, Towler DA, Giachelli CM, Hofmann-Bowman MA, Mortlock DP, Rogers MB, Sadeghi MM, Aikawa E. 2014. Calcific aortic valve disease: A consensus summary from the alliance of investigators on calcific aortic valve disease. Arterioscler Thromb Vasc Biol. 34: 2387-2393. Abstract

Ellis KL, Zhou Y, Beshansky JR, Ainehsazan E, Yang Y, Selker HP, Huggins GS, Cupples LA, Peter I. 2014. Genetic variation at glucose and insulin trait loci and response to glucose-insulin-potassium (GIK) therapy: the IMMEDIATE trial. Pharmacogenomics 15: 55-62. Abstract

Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, Bart BA, Bull DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL, O'Meara E, Tang WH, Starling RC, Butler J, Deswal A, Felker GM, O'Connor CM, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, Dávila-Román VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM; NHLBI Heart Failure Clinical Research Network. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 310: 2533-2543. Abstract

Peter I, Papandonatos GD, Belalcazar LM, Yang Y, Erar B, Jakicic JM, Unick JL, Balasubramanyam A, Lipkin EW, Delahanty LM, Wagenknecht LE, Wing RR, McCaffery JM, Huggins GS. 2013. Genetic modifiers of cardiorespiratory fitness response to lifestyle intervention. Med Sci Sports Exerc. 46: 302-311. Abstract

Huggins GS, Papandonatos GD, Erar B, Belalcazar LM, Brautbar A, Ballantyne C, Kitabchi AE, Wagenknecht LE, Knowler WC, Pownall HJ, Wing RR, Peter I, McCaffery JM. 2013. Do genetic modifiers of HDL-C and triglyceride levels also modify their response to a lifestyle intervention in the setting of obesity and type-2 diabetes mellitus? The Look AHEAD Study. Circ Cardiovasc Genet. 6: 391-399. Abstract

Arya MA, Tai AK, Wooten EC, Parkin CD, Kudryavtseva E, Huggins GS. 2013. Notch pathway activation contributes to inhibition of C2C12 myoblast differentiation by ethanol. PLoS ONE 8: e71632 . Abstract

Wachman EM, Hayes MJ, Brown MS, Paul J, Harvey-Wilkes K, Terrin N, Huggins GS, Aranda JV, Davis JM. 2013. Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA 309: 1821-1827. Abstract

Warner PJ, Al-Quthami A, Brooks EL, Kelley-Hedgepeth A, Patvardhan E, Kuvin JT, Heffernan KS, Huggins GS. 2013. Augmentation index and aortic stiffness in bicuspid aortic valve patients with non-dilated proximal aortas. BMC Cardiovasc Disord. 13: 19. Abstract

Wooten EC, Hebl VB, Wolf MJ, Greytak SR, Orr N, Draper I, Calvino JE, Kapur NK, Maron MS, Kullo IJ, Ommen SR, Bos JM, Ackerman MJ, Huggins GS. 2013. Formin homology 2 domain containing 3 (FHOD3) variants associated with hypertrophic cardiomyopathy. Circ Cardiovasc Genet. 6:10-18. Abstract

Miller VM, Petterson TM, Jeavons EN, Lnu AS, Rider DN, Heit JA, Cunningham JM, Huggins GS, Hodis HN, Budoff MJ, Santoro N, Hopkins PN, Lobo RA, Manson JE, Naftolin F, Taylor HS, Harman SM, de Andrade M. 2013. Genetic polymorphisms associated carotid artery intima-media thickness and coronary artery calcification in women of the Kronos Early Estrogen Prevention Study. Physiol Genomics. 45: 79-88. Abstract

Siegfried JD, Morales A, Kushner JD, Burkett E, Cowan J, Mauro AC, Huggins GS, Li D, Norton N, Hershberger RE. 2013. Return of genetic results in the familial dilated cardiomyopathy research project. J Genet Couns. 22: 164-174. Abstract

Halder I, Kip KE, Mulukutla SR, Aiyer AN, Marroquin OC, Huggins GS, Reis SE. 2012. Biogeographic ancestry, self-identified race, and admixture-phenotype associations in the Heart SCORE Study. Am J Epidemiol. 176: 146-155. Abstract